EXACT Therapeutic’s Acoustic Cluster Therapy to be presented at the Ninth International Cancer lmmunotherapy Conference
EXACT Therapeutic’s Acoustic Cluster Therapy to be presented at the Ninth International Cancer lmmunotherapy Conference
Oslo, Norway, 9 September 2025. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce that early, encouraging pre-clinical data on EXACT’s proprietary Acoustic Cluster Therapy (ACT®) in immune oncology will be presented at the upcoming Ninth International Cancer lmmunotherapy Conference (CICON25), during September 10-12, 2025, in Utrecht, The Netherlands.
The following two posters will be presented:
• Title: Acoustic Cluster Therapy (ACT) increases Anti-PD1 checkpoint inhibitor uptake in prostate
cancer in mice
• In collaboration with NTNU, the Norwegian University of Science and Technology
• Title: Evaluation of the immunostimulatory potential of Acoustic Cluster Therapy (ACT®) in melanoma
and breast cancer models in mice
• In collaboration with ICR, the Institute of Cancer Research, UK
The posters will be made available on the Company’s website.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: [email protected]